Highest-materiality recent filing
Bicycle Therapeutics reports positive Duravelo-2 mUC data with lower toxicity vs SOC
Zelenectide + pembrolizumab: 58% confirmed ORR (15/26) at optimal dose in first-line mUC; 62% with later response.
Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff
Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.
Bicycle Therapeutics: nuzefatide 40% ORR in EphA2+ mUC; Phase 2 PDAC trial dosed
Nuzefatide + nivolumab in 14 mUC patients: 40% ORR in EphA2+ tumors; 100% ORR (3/3) in MMAE-naïve EphA2+ tumors.
Deprioritizes zelenectide in mUC; converts Duravelo-2 to randomized Phase 2 after regulatory feedback says trial design no longer acceptable for approval.
Bicycle Therapeutics appoints Travis Thompson as CFO, succeeding Alethia Young
Travis Thompson appointed CFO effective Jan 29, 2026; previously SVP & Chief Accounting Officer since June 2023.
Bicycle Therapeutics Q3 net loss $59.1M; lead drug regulatory update delayed to Q1 2026
Net loss of $59.1M ($0.85 per share) vs $50.8M ($0.74) in Q3 2024; R&D expenses up 21% to $58.4M.
Bicycle Therapeutics Q2 net loss widens to $1.14/share; cuts workforce 30% to extend runway
Net loss $79.0M ($1.14/share) vs $39.8M ($0.77) a year ago; R&D spend rose 77% to $71.0M.
Bicycle Therapeutics Q1 net loss $60.8M; cash $793M; Duravelo-3 trial recruiting
Net loss of $60.8M ($0.88 per share) vs $26.6M ($0.62) in Q1 2024; R&D expense $59.1M (+69% YoY).
Pierre Legault and Richard Kender to retire from board after AGM June 17, 2025; Felix Baker to become chairman.
Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.
Updated Phase 1 Duravelo-1 data: 65% ORR (13/20 evaluable) in 1L cisplatin-ineligible mUC; 50% confirmed ORR.
Bicycle Therapeutics Reports Positive Zelenectide Pevedotin Data in Multiple Cancers
Zelenectide pevedotin plus pembrolizumab showed 60% ORR in 22 first-line cisplatin-ineligible mUC patients.
Net loss $50.8M ($0.74/shr) in Q3 2024 vs $49.9M ($1.26/shr) in Q3 2023; R&D spend $48.3M, up from $39.9M.
Bicycle Therapeutics reports positive ESMO 2024 data: 45% ORR for zelenectide pevedotin in mUC
Zelenectide pevedotin monotherapy in mUC: 45% ORR (38 evaluable patients), 11.1 months median duration of response.
Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE
Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.
Sold 25,933,706 ADSs (and non-voting ordinary shares in lieu) at $21.42/share for gross proceeds of ~$555M.
Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated
Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.
Max materiality 0.90 · Median 0.68 · Most common event other_material